Acknowledgement
Supported by : Korean Society of Cardiology, Korea University, National Research Foundation (NRF) of Korea
References
- Stewart S, Murphy NF, Walker A, McGuire A, McMurray JJ. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart 2004;90:286-92. https://doi.org/10.1136/hrt.2002.008748
- Allessie M, Ausma J, Schotten U. Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res 2002;54:230-46. https://doi.org/10.1016/S0008-6363(02)00258-4
- Burstein B, Nattel S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol 2008;51:802-9. https://doi.org/10.1016/j.jacc.2007.09.064
- Goette A, Bukowska A, Lendeckel U, et al. Angiotensin II receptor blockade reduces tachycardia-induced atrial adhesion molecule expression. Circulation 2008;117:732-42. https://doi.org/10.1161/CIRCULATIONAHA.107.730101
- Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. Lancet 2009;373:155-66. https://doi.org/10.1016/S0140-6736(09)60040-4
- Nakashima H, Kumagai K. Reverse-remodeling effects of angiotensin II type 1 receptor blocker in a canine atrial fibrillation model. Circ J 2007;71:1977-82. https://doi.org/10.1253/circj.71.1977
- Kumagai K, Nakashima H, Urata H, Gondo N, Arakawa K, Saku K. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol 2003;41:2197-204. https://doi.org/10.1016/S0735-1097(03)00464-9
- Vasiljevic JD, Popovic ZB, Otasevic P, et al. Myocardial fibrosis assessment by semiquantitative, point-counting and computer-based methods in patients with heart muscle disease: a comparative study. Histopathology 2001;38:338-43. https://doi.org/10.1046/j.1365-2559.2001.01101.x
- Nattel S. Defining "culprit mechanisms" in arrhythmogenic cardiac remodeling. Circ Res 2004;94:1403-5. https://doi.org/10.1161/01.RES.0000133229.19586.bb
- Everett TH 4th, Olgin JE. Atrial fibrosis and the mechanisms of atrial fibrillation. Heart Rhythm 2007;4(3 Suppl):S24-7. https://doi.org/10.1016/j.hrthm.2006.12.040
- Freestone B, Beevers DG, Lip GY. The renin-angiotensin-aldosterone system in atrial fibrillation: a new therapeutic target? J Hum Hypertens 2004;18:461-5. https://doi.org/10.1038/sj.jhh.1001694
- Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol Rev 2011;91:265-325. https://doi.org/10.1152/physrev.00031.2009
- Lin CS, Pan CH. Regulatory mechanisms of atrial fibrotic remodeling in atrial fibrillation. Cell Mol Life Sci 2008;65:1489-508. https://doi.org/10.1007/s00018-008-7408-8
- Li D, Shinagawa K, Pang L, et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 2001;104:2608-14. https://doi.org/10.1161/hc4601.099402
- He X, Gao X, Peng L, et al. Atrial fibrillation induces myocardial fibrosis through angiotensin II type 1 receptor-specific Arkadia-mediated downregulation of Smad7. Circ Res 2011;108:164-75. https://doi.org/10.1161/CIRCRESAHA.110.234369
- Kim HS, No CW, Goo SH, et al. An angiotensin receptor blocker prevents arrhythmogenic left atrial remodeling in a rat post myocardial infarction induced heart failure model. J Korean Med Sci 2013;28:700-8. https://doi.org/10.3346/jkms.2013.28.5.700
- Park JH, Lee JS, Ko YG, et al. Histological and biochemical comparisons between right atrium and left atrium in patients with mitral valvular atrial fibrillation. Korean Circ J 2014;44:233-42. https://doi.org/10.4070/kcj.2014.44.4.233
- Das UN. Is angiotensin-II an endogenous pro-inflammatory molecule? Med Sci Monit 2005;11:RA155-62.
- Takagishi T, Murahashi N, Azagami S, et al. Effect of angiotensin II and thromboxane A2 on the production of matrix metalloproteinase by human aortic smooth muscle cells. Biochem Mol Biol Int 1995;35:265-73.
- Wachtell K, Hornestam B, Lehto M, et al. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005;45:705-11. https://doi.org/10.1016/j.jacc.2004.06.080
Cited by
- Clinical and Echocardiographic Risk Factors Predict Late Recurrence after Radiofrequency Catheter Ablation of Atrial Fibrillation vol.9, pp.None, 2016, https://doi.org/10.1038/s41598-019-43283-7
- Left atrial fibrosis in atrial fibrillation: Mechanisms, clinical evaluation and management vol.25, pp.6, 2016, https://doi.org/10.1111/jcmm.16350